↧
ACADIA Busts Schizophrenia Trials (ACAD)
ACADIA Pharmaceuticals (NASDAQ: ACAD) is going to be in for a rough day. The company announced that the results from its ACP-104 phase IIb schizophrenia trial did not meet its primary endpoint. Not...
View ArticleBiotech Implosion: Vanda Pharmaceuticals (VNDA)
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) is seeing a major implosion this morning. The company has disclosed that it received a dreaded FDA not-approvable letter on its iloperidone. This was its...
View Article